Survival Outcomes of Gynecologic Oncology Patients at Assiut University

November 14, 2025 updated by: Esraa Mohamed Farouk, Assiut University

Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)

This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.

Study Type

Observational

Enrollment (Estimated)

200

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

All female patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancer) and treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025, will be included. Patients of all ages and backgrounds are eligible. Exclusion criteria are non-gynecological cancers, metastatic cancers originating outside the gynecologic tract, incomplete medical records, or significant comorbidities that independently affect survival (e.g., advanced heart failure, severe liver or renal disease, or unrelated terminal illnesses).

Description

Inclusion Criteria:

- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)

Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025

All age groups included

Exclusion Criteria:

- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract

Patients with incomplete medical records (e.g., missing pathology reports or treatment details)

Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall Survival
Time Frame: 4 years
Overall survival (OS) is defined as the duration of time from the date of cancer diagnosis or initiation of treatment until death from any cause. Patients will be censored at the date of last follow-up if alive at study end. This outcome will provide a direct estimate of survival rates among gynecological oncology patients treated at Assiut University Hospital.
4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

February 1, 2027

Study Registration Dates

First Submitted

November 14, 2025

First Submitted That Met QC Criteria

November 14, 2025

First Posted (Actual)

November 18, 2025

Study Record Updates

Last Update Posted (Actual)

November 18, 2025

Last Update Submitted That Met QC Criteria

November 14, 2025

Last Verified

November 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • Gynecological Oncology Outcome

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gynaecological Oncology

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe